$ADIA featured in a new Nasdaq article out that is spotlighting smaller stem cell companies:
https://www.nasdaq.com/press-release/future-s...2025-03-04
Quote:ADIA Nutrition Inc. (OTC: ADIA) is on a mission to transform healthcare through innovation in regenerative medicine and premium organic supplements. Operating under two key divisions—its supplement arm and Adia Med, its medical division—the company is making waves in the fast growing global stem cell market. With cutting-edge therapies like Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT), ADIA Nutrition is empowering patients to address conditions ranging from autoimmune disorders to orthopedic injuries.
2025 has been a landmark year for ADIA Nutrition, with groundbreaking achievements that emphasize innovation and accessibility. In March, the company celebrated the FDA registration of Adia Vita, its premier stem cell product. This allows Adia Vita to be distributed nationwide, significantly expanding access to regenerative medicine. "This acceptance reflects Adia Labs' commitment to broadening access," said Larry Powalisz, CEO of ADIA Nutrition. The registration enhances patient access and opens new revenue opportunities.
In February, ADIA announced a strategic expansion plan by partnering with elite Medical Spas to create satellite locations across the U.S. This low-cost model will offer treatments like UCB-SC therapies and stem cell injectables to health-conscious regions, tapping into an existing customer base and creating revenue streams via service fees, royalties, and equity interests. "This expansion is a testament to our commitment to making therapies more accessible," Powalisz said.
The launch of Adia Labs LLC in February solidified ADIA’s leadership in regenerative medicine. Adia Labs introduced AdiaVita, a high-potency stem cell product containing 100 million cells and 3 trillion exosomes per dose, designed for clinical research and therapeutic use. A future product, AdiaLink, will contain 3.5 trillion exosomes, pushing the boundaries of medical science. "We are advancing medical science while maintaining the highest standards of safety and quality," Powalisz stated.
A key to ADIA’s success is its partnership with a premier FDA-approved laboratory, ensuring the highest quality stem cell and exosome products. Each dose is third-party verified for purity, potency, and safety, making it a trusted choice for medical professionals. "After months of due diligence, we offer the best quality therapies per treatment," Powalisz noted. This partnership guarantees a steady supply of top-tier products.
ADIA is also working to secure private insurance coverage for treatments like aHSCT and injectable stem cells, reducing the financial burden on patients and expanding access. "Registering with the AHCA is a monumental step in providing open access to our therapies," Powalisz said. The company’s integration into the mainstream healthcare ecosystem is gaining traction, with several patients already preapproved by private insurers.
The Winter Park, Florida clinic has exceeded financial expectations in its first month of operation, offering FDA-compliant treatments for conditions like Multiple Sclerosis, hip issues, and joint pain. "Many patients have traveled abroad for treatments we now offer locally," said Dr. Monica Sher, Chief Stem Cell Medical Officer at Adia Med.
Looking ahead, ADIA plans to replicate its successful clinic model in new markets, expand satellite locations, and complete its uplisting to the OTCQB Venture Market. With aspirations for a Nasdaq listing, the company could be poised for significant growth. "From January's financial win to February's breakthroughs, we’re redefining healthcare possibilities," Powalisz added. "We’re committed to innovation and sustainable growth."
For investors, ADIA offers a unique opportunity to be part of a company revolutionizing healthcare. With its innovative treatments, strategic partnerships, and commitment to quality, ADIA Nutrition is well-positioned to lead the regenerative medicine industry.
https://www.nasdaq.com/press-release/future-s...2025-03-04
